Back to top

Image: Bigstock

3 Medical Stocks Displaying Remarkable Relative Strength in 2022

Read MoreHide Full Article

It’s been a historically volatile market, with a hawkish Federal Reserve and geopolitical issues spoiling the fun for stocks all year.

However, there have been a fair number of stocks in 2022 displaying remarkable relative strength year-to-date.

Relative strength focuses on stocks or other assets that have performed well relative to the market as a whole or a relevant benchmark.

Three stocks from the Zacks Medical Sector – UnitedHealth Group Inc. (UNH - Free Report) , McKesson Corp. (MCK - Free Report) , and AstraZeneca PLC (AZN - Free Report) – have displayed a substantial amount of relative strength year-to-date, as we can see in the chart below.

Zacks Investment Research
Image Source: Zacks Investment Research

Let’s take a deeper dive into each one.

UnitedHealth Group Inc.

UnitedHealth provides a wide range of health care products and services, such as health maintenance organizations (HMOs), point of service plans (POS), preferred provider organizations (PPOs), and managed fee-for-service programs.

UNH has shown a commendable commitment to its shareholders – UnitedHealth has upped its dividend payout five times over the last five years with a five-year annualized dividend growth rate of a substantial 17.6%.

The company’s 1.3% annual yield is just slightly lower than its Zacks Sector average of 1.5%.

Zacks Investment Research
Image Source: Zacks Investment Research

Further, the company knows how to generate serious cash – UNH’s free cash flow came in at a sizable $6.2 billion in its latest quarter, penciling in a double-digit 30% sequential increase and a 25% Y/Y uptick.

Zacks Investment Research
Image Source: Zacks Investment Research

To top it off, UnitedHealth carries a notably strong growth profile – earnings are forecasted to soar 15% in FY22 and an additional 13% in FY23.

Zacks Investment Research
Image Source: Zacks Investment Research

McKesson Corp.

McKesson Corp. is a healthcare services and information technology company operating through two segments: Distribution Solutions and Technology Solutions.

MCK’s near-term earnings outlook has turned notably bright over the last several months, helping land the stock into a favorable Zacks Rank #2 (Buy).

Zacks Investment Research
Image Source: Zacks Investment Research

In addition, the company carries favorable valuation characteristics, further bolstered by its Value Style Score of an A.

McKesson’s forward earnings multiple sits at 14.2X, representing an enticing 31% discount relative to its Zacks Medical Sector.

Zacks Investment Research
Image Source: Zacks Investment Research

Like UNH, McKesson’s growth profile is notable; the Zacks Consensus EPS Estimate for the company’s current fiscal year (FY23) resides at $24.42, penciling in Y/Y bottom line growth of more than 3%.

And in FY24, earnings are forecasted to climb a further 7%.

Zacks Investment Research
Image Source: Zacks Investment Research

AstraZeneca PLC

AstraZeneca is one of the largest biopharmaceutical companies in the world. Its business can be broken down into separate lines based on therapeutic classes, including cardiovascular, respiratory, immunology, oncology, rare diseases, and others.  

For those seeking an income stream, AstraZeneca has that covered; the company’s annual dividend yields 1.6%, paired with a sizable 6.6% five-year annualized dividend growth rate.

Undoubtedly a positive, the company has upped its dividend payout five times over the last five years.

Zacks Investment Research
Image Source: Zacks Investment Research

AZN currently carries a 17.1X forward earnings multiple, nicely beneath its 22.3X five-year median and reflecting a sizable 17% discount relative to its Zacks Sector.

Further, AstraZeneca carries a Style Score of a B for Value.

Zacks Investment Research
Image Source: Zacks Investment Research

Perhaps the biggest highlight of all is the company’s forecasted growth – for AZN’s current fiscal year (FY22), the Zacks Consensus EPS Estimate of $3.31 pencils in a stellar 25% Y/Y uptick in earnings.

And in FY23, the company’s bottom line looks to expand a further double-digit 11.4%.

Zacks Investment Research
Image Source: Zacks Investment Research

Bottom Line

While the market’s price action has undoubtedly been disheartening in 2022, some stocks are still weathering the storm better than most.

All three stocks above have widely outperformed the S&P 500 in 2022, telling us that market participants have defended shares at a much higher level than others.

For investors searching for stocks displaying relative strength in 2022 paired with a strong growth roadmap, UnitedHealth Group Inc. (UNH - Free Report) , McKesson Corp. (MCK - Free Report) , and AstraZeneca PLC (AZN - Free Report) all deserve a watchlist spot.


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


AstraZeneca PLC (AZN) - free report >>

UnitedHealth Group Incorporated (UNH) - free report >>

McKesson Corporation (MCK) - free report >>

Published in